HER2 as a prognostic factor in breast cancer.

Abstract:

:HER2 amplification/overexpression is a marker of poor prognosis in breast cancer. The prognostic impact of HER2 positivity is lower in node-negative compared with node-positive women. The only significant, independent prognostic factors in breast cancer are node status, HER2 status and menopausal status. HER2-positive tumors also contain p53 abnormalities, tend to be hormone receptor and bcl-2 negative, have lymphoid infiltration (LI) and a high mitotic index. Patients with LI who are HER2 positive have a better prognosis than those who are HER2 negative, whereas HER2-positive patients without LI have a significantly worse prognosis than HER2-negative patients. Morphological and biological alterations appear to identify two categories of breast tumor. Two hypotheses may explain the progression to two tumor types: (1) atypical ductal hyperplasia (ADH) is a precursor of ductal carcinoma in situ (DCIS), which is a precursor of invasive ductal carcinoma (IDC); or (2) ADH is a precursor of HER2-negative IDC whereas DCIS is a precursor of HER2-positive IDC. The second theory fits well with two breast cancer subsets and the characteristics of ADH and DCIS. The first type of IDC occurs in older patients, progresses slowly due to estrogen dependency but is aggressive long term. The other type progresses rapidly, is HER2 positive and is more likely to occur in young patients.

journal_name

Oncology

journal_title

Oncology

authors

Ménard S,Fortis S,Castiglioni F,Agresti R,Balsari A

doi

10.1159/000055404

subject

Has Abstract

pub_date

2001-01-01 00:00:00

pages

67-72

eissn

0030-2414

issn

1423-0232

pii

55404

journal_volume

61 Suppl 2

pub_type

杂志文章,评审

相关文献

ONCOLOGY文献大全
  • Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.

    abstract::Breast tumorigenesis is a continuum from preinvasive lesions to early breast cancer and advanced disease. In this article the data supporting the use of the aromatase inhibitor anastrozole in postmenopausal women across this continuum are reviewed. In advanced disease, anastrozole has a significant survival benefit an...

    journal_title:Oncology

    pub_type: 杂志文章,评审

    doi:10.1159/000091180

    authors: Nabholtz JM

    更新日期:2006-01-01 00:00:00

  • Testing prospective anticancer drugs against human tumors using simple in vivo models.

    abstract::The activities of established and experimental antitumor drugs were tested against the BRO and MeWo human melanomas transplanted in the subrenal capsule of phenotypically immunocompetent (CBA x C57BL/6)F1 mice. Immunosuppression was achieved with preliminary whole-body radiation, and cytological examination showed tha...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000227400

    authors: Ryabkova VI,Lockshin A,Strukov IG,Sokolova VK

    更新日期:1994-11-01 00:00:00

  • Thermochemosensitivity: augmentation by hyperthermia of cytotoxicity of anticancer drugs against human colorectal cancers, measured by the human tumor clonogenic assay.

    abstract::Thermochemosensitivity was examined in vitro by a human tumor clonogenic assay (HTCA) using specimens obtained surgically from 43 patients with colorectal cancer. We found that the percentages of patients whose cells showed higher sensitivity (greater than 70% inhibition of colony formation) to hyperthermia alone were...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226568

    authors: Murakami A,Koga S,Maeta M

    更新日期:1988-01-01 00:00:00

  • Implications of flow cytometry in preoperative detection of biologic variables of gastric cancer and malignant condition of gastric remnant cells obtained by endoscopic biopsy.

    abstract::Flow cytometric (FCM) DNA studies were performed on cell suspensions obtained by endoscopic biopsy in 73 patients with gastric cancer and in 61 patients with gastric remnant. In cancer, DNA aneuploidies were detected in 49 tumors (67.1%), including 51.7% (15/29) of early gastric cancers and 77.3% (34/44) of advanced g...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000227389

    authors: Kimura H,Kanno M,Takamura H,Arakawa H,Maeda K,Uogishi M,Sodani H,Kawashima T

    更新日期:1994-11-01 00:00:00

  • Characterization of vincristine-resistant HOB1 lymphoma cell line showing the classical MDR phenotype and altered expression of membrane glycoproteins.

    abstract::A multidrug-resistant (MDR) cell line isolated from HOB1 lymphoma cells was characterized. The MDR phenotype in this cell line was typified by resistance to vincristine with varying degrees of cross-resistance to Adriamycin, colcemid and actinomycin D. Decreased intracellular [3H]vincristine with concurrent increase i...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000227300

    authors: Lee WP,Lee CL

    更新日期:1994-01-01 00:00:00

  • Immunological properties of lymphoblasts and lymphocytes in children with acute lymphatic or undifferentiated leukemia.

    abstract::In 35 children with acute lymphatic or undifferentiated leukemia, immunological properties of normal lymphocytes and lymphoblasts were investigated. In most cases the number of circulating normal lymphocytes with surface or B markers and delayed type hypersensitivity was depressed. On the other hand, the response to m...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000225300

    authors: Winterleitner H,Rella W,Eibl M,Krepler P

    更新日期:1978-01-01 00:00:00

  • Pharmacokinetic study of S-1 in patients in whom inulin clearance was measured.

    abstract:OBJECTIVE:This pharmacokinetic study of S-1 was conducted in patients in whom glomerular filtration rate (GFR) was directly measured to explore the possibility of adjusting the S-1 dose on the basis of GFR in patients with normal or nearly normal renal function. METHODS:S-1 was given to 12 patients twice daily for 28 ...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000337232

    authors: Ando Y,Kawada K,Inada M,Morita S,Mitsuma A,Yasuda Y,Hiramatsu M,Fujimoto Y,Fujita K

    更新日期:2012-01-01 00:00:00

  • Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).

    abstract:BACKGROUND:This open-label, randomized phase III trial evaluated larotaxel/cisplatin versus gemcitabine/cisplatin as first-line treatment for locally advanced (T4b) or metastatic urothelial tract or bladder cancer. METHODS:Patients were randomized to larotaxel 50 mg/m(2) with cisplatin 75 mg/m(2) every 3 weeks (larota...

    journal_title:Oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1159/000354085

    authors: Sternberg CN,Skoneczna IA,Castellano D,Theodore C,Blais N,Voog E,Bellmunt J,Peters F,Le-Guennec S,Cerbone L,Risse ML,Machiels JP

    更新日期:2013-01-01 00:00:00

  • Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.

    abstract:PURPOSE:This phase I study (EudraCT No. 2006-001177-25) investigated aflibercept, a vascular endothelial growth factor decoy receptor protein (VEGF Trap), in combination with docetaxel, cisplatin, and 5-fluorouracil in patients with advanced solid tumors. PATIENTS AND METHODS:Patients received 2, 4, or 6 mg/kg of intr...

    journal_title:Oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1159/000440958

    authors: Bahleda R,Baker J,Massard C,Gadgeel SM,Rogers JE,Izzedine H,Deutsch E,Garris JL,Khan A,Boelle E,Assadourian S,Soria JC,Ajani JA

    更新日期:2016-01-01 00:00:00

  • Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.

    abstract:OBJECTIVE:An increasing number of patients with advanced pancreatic or biliary tract cancer who progress after a gemcitabine-containing regimen are candidates for further chemotherapy. We therefore evaluated a fully oral regimen of capecitabine and celecoxib (CapCel) as second-line treatment in these patients. METHODS...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000205388

    authors: Pino MS,Milella M,Gelibter A,Sperduti I,De Marco S,Nuzzo C,Bria E,Carpanese L,Ruggeri EM,Carlini P,Cognetti F

    更新日期:2009-01-01 00:00:00

  • Impact of Socioeconomic Status and Ethnicity on Melanoma Presentation and Recurrence in Caucasian Patients.

    abstract:OBJECTIVES:The impact of ethnicity and the socioeconomic status (SES) among Caucasians is not well studied. Here, we examine the impact of income on melanoma presentation and prognosis within a Caucasian cohort, accounting for ethnicity, as some reports suggest increased melanoma incidence in Ashkenazi Jewish (AJ) BRCA...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000441524

    authors: Salvaggio C,Han SW,Martires K,Robinson E,Madankumar R,Gumaste P,Polsky D,Stein J,Berman R,Shapiro R,Zhong J,Osman I

    更新日期:2016-01-01 00:00:00

  • Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center.

    abstract::Between June 1980 and December 1984, 88 patients with stage III-IV ovarian carcinoma were entered in a study evaluating the role of debulking surgery and chemotherapy consisting of cyclophosphamide, doxorubicin, and cisplatin intravenously on day 1, every 4 weeks (CAP-1). The results after a median follow-up of 62 mon...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226801

    authors: Wils JA

    更新日期:1990-01-01 00:00:00

  • Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study.

    abstract::The encouraging results that have been reported for cisplatin combination chemotherapy in a minority of patients with cancer of unknown primary (CUP) together with the previously shown equal activity of carboplatin in this setting, prompted us to investigate the effectiveness of a carboplatin-containing regimen in a p...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000011890

    authors: Briasoulis E,Tsavaris N,Fountzilas G,Athanasiadis A,Kosmidis P,Bafaloukos D,Skarlos D,Samantas E,Pavlidis N

    更新日期:1998-09-01 00:00:00

  • Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update.

    abstract::In the 2010 version of the Japan Society of Hepatology (JSH) consensus-based treatment algorithm for the management of hepatocellular carcinoma (HCC), transarterial chemoembolization (TACE) failure/refractoriness was defined assuming the use of superselective lipiodol TACE, which has been widely used worldwide and par...

    journal_title:Oncology

    pub_type: 共识发展会议,杂志文章,实务指引,评审

    doi:10.1159/000368142

    authors: Kudo M,Matsui O,Izumi N,Kadoya M,Okusaka T,Miyayama S,Yamakado K,Tsuchiya K,Ueshima K,Hiraoka A,Ikeda M,Ogasawara S,Yamashita T,Minami T,Liver Cancer Study Group of Japan.

    更新日期:2014-01-01 00:00:00

  • Immunohistochemical study of ras p21 expression in human gastric cancers and benign lesions.

    abstract::Expression of ras p21 in human gastric cancers, benign lesions and normal tissues was immunohistochemically evaluated by the avidin-biotin peroxidase complex (ABC) method with anti-ras p21 monoclonal antibody rp-28. Positive p21 immunoreactivity was shown in 23 (77%) of 30 gastric cancers, in 13 (48%) of 27 benign les...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226728

    authors: Nakajima K,Kuzumaki N,Oda A,Kobayashi H,Katoh H,Tanabe T

    更新日期:1989-01-01 00:00:00

  • Gastric non-Hodgkin's lymphoma after successful treatment of Hodgkin's disease.

    abstract::A patient seen at presentation for Hodgkin's disease (HD) at stage IV B was successfully treated with MOPP. In remission he developed coeliac disease, controlled by dietary measures, but 26 months after the end of chemotherapy a severe dyspeptic syndrome appeared; endoscopy and barium meal suggested the presence of a ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226345

    authors: Eridani S,Singh AK

    更新日期:1986-01-01 00:00:00

  • The roles of serum leptin concentration and polymorphism in leptin receptor gene at codon 109 in breast cancer.

    abstract:AIMS:We investigated the relationship between serum leptin concentrations and polymorphism of the leptin receptor gene and breast cancer. METHODS:Serum leptin concentrations were measured by enzyme-linked immunosorbent assay in 47 women with invasive breast cancer compared with 41 age-matched controls without cancer. ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000111097

    authors: Liu CL,Chang YC,Cheng SP,Chern SR,Yang TL,Lee JJ,Guo IC,Chen CP

    更新日期:2007-01-01 00:00:00

  • Serum alphafetoprotein in bladder carcinoma.

    abstract::112 cases, of varying ages, which were diagnosed as having carcinoma of the bladder by cystoscopy and biopsy from the tumor, were investigated for the presence of alphafetoprotein (AFP) in the sera. 59 (52.6%) out of the total, showed positive results, and no false positive results occured. Radioimmunoassay was capabl...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000225188

    authors: Alsabti EA

    更新日期:1977-01-01 00:00:00

  • A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale study.

    abstract:OBJECTIVE:To evaluate two docetaxel-based regimens as first-line treatment in advanced breast cancer patients. METHODS:Patients were randomly assigned to docetaxel/gemcitabine (arm A: docetaxel 75 mg/m(2) on day 1, gemcitabine 1,000 mg/m(2) on days 1 and 8) or docetaxel/capecitabine (arm B: docetaxel 75 mg/m(2) on day...

    journal_title:Oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1159/000334432

    authors: Vici P,Giotta F,Di Lauro L,Sergi D,Vizza E,Mariani L,Latorre A,Pizzuti L,D'Amico C,Giannarelli D,Colucci G

    更新日期:2011-01-01 00:00:00

  • Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.

    abstract:INTRODUCTION:Carcinoma of the biliary system is a rare tumor entity, and patients with advanced disease face a dismal prognosis. Because of the absence of standard chemotherapy for advanced biliary carcinoma, we have performed two consecutive studies to evaluate the clinical potential of 5-fluorouracil, leucovorin and ...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000011961

    authors: Raderer M,Hejna MH,Valencak JB,Kornek GV,Weinländer GS,Bareck E,Lenauer J,Brodowicz T,Lang F,Scheithauer W

    更新日期:1999-04-01 00:00:00

  • Phase II evaluation of 5-fluorouracil, folinic acid and cisplatin in advanced-stage colorectal adenocarcinoma.

    abstract::Twenty-seven patients with advanced measurable colorectal carcinoma were treated with a combination protocol consisting of folinic acid (FA) 200 mg/m2 i.v. bolus followed by 5-fluorouracil (5-FU) 550 mg/m2, and cisplatin (CIS) 20 mg/m2 each administered as a 2-hour i.v. infusion. Treatment was given on 4 consecutive d...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226719

    authors: Scheithauer W,Depisch D,Schiessel R,Ludwig H

    更新日期:1989-01-01 00:00:00

  • Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.

    abstract::Sorafenib, an oral multikinase inhibitor, has demonstrated clinical efficacy in patients with advanced hepatocellular carcinoma (HCC). However, in the SHARP trial (Sorafenib HCC Assessment Randomized Protocol trial) and the Asia-Pacific trial (conducted in the Asia-Pacific region), no cases of complete response (CR) w...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000333279

    authors: Inuzuka T,Nishikawa H,Sekikawa A,Takeda H,Henmi S,Sakamoto A,Saito S,Kita R,Kimura T,Osaki Y,Kudo M

    更新日期:2011-01-01 00:00:00

  • Cancer in humans: exposures and responses in a real world.

    abstract::Cancer causation in humans is at least a three-dimensional problem too often viewed from only two dimensions, especially as far as the two-dimensional results (dose versus response) of cancer induction tests in animals are viewed. The expression of a cancer represents a critical convergence of additional factors in th...

    journal_title:Oncology

    pub_type: 杂志文章,评审

    doi:10.1159/000225113

    authors: Kolbye AC Jr

    更新日期:1976-01-01 00:00:00

  • Preoperative serum alpha-L-fucosidase activity as a prognostic marker in colorectal cancer.

    abstract:OBJECTIVES:The aim of this study was to examine the prognostic value of the preoperative serum alpha-L-fucosidase (AFU) activity in colorectal cancer and to assess whether it could add prognostic information that Dukes' stages do not give. METHODS:A postoperative follow-up of 137 colorectal cancer patients was perform...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000066521

    authors: Ayude D,Páez De La Cadena M,Martínez-Zorzano VS,Fernández-Briera A,Rodríguez-Berrocal FJ

    更新日期:2003-01-01 00:00:00

  • Evaluation of Systemic Inflammatory Response Biomarkers in Patients Receiving Chemotherapy for Unresectable and Recurrent Advanced Gastric Cancer.

    abstract:BACKGROUND:The present study sought to evaluate an inflammation-based prognostic score (Glasgow prognostic score, GPS) and the neutrophil to lymphocyte ratio (NLR) as prognostic factors in patients receiving chemotherapy for advanced gastric cancer. METHODS:The study enrolled 224 patients who received chemotherapy for...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000446373

    authors: Namikawa T,Munekage E,Munekage M,Maeda H,Yatabe T,Kitagawa H,Kobayashi M,Hanazaki K

    更新日期:2016-01-01 00:00:00

  • Clinical relevance of sialyltransferases ST6GAL-I and ST3GAL-III in gastric cancer.

    abstract::Aberrant glycosylation of membrane components due to specific alterations of glycosyltransferase activity is a common feature of carcinoma cells and is usually associated with invasion and metastasis. In a prospective study, the enzyme activity of the sialyltransferases ST6GAL-I and ST3GAL-III was studied in gastric c...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000072339

    authors: Gretschel S,Haensch W,Schlag PM,Kemmner W

    更新日期:2003-01-01 00:00:00

  • Stem cell relationships and the origin of gastrointestinal cancer.

    abstract::Gastrointestinal stem cells have the capacity for long-term self-replication and the ability to give rise to all other epithelial cell lineages. These properties make them essential since they maintain tissue homeostasis by regulating cell turnover depending on the current demand. However, they are also important play...

    journal_title:Oncology

    pub_type: 杂志文章,评审

    doi:10.1159/000086625

    authors: Schier S,Wright NA

    更新日期:2005-01-01 00:00:00

  • Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen.

    abstract::A cultured cell line (SHIN-3) derived from a human ovarian serous cystadenocarcinoma which consistently produces two tumor markers, CA-125 and tissue polypeptide antigen (TPA) was established. After 1 week of culture of 1 x 10(5) cells, high levels of tumor marker were observed (the total CA-125 release was 1,500 U an...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226813

    authors: Imai S,Kiyozuka Y,Maeda H,Noda T,Hosick HL

    更新日期:1990-01-01 00:00:00

  • The low-grade lymphoproliferative disorders.

    abstract::Rapid advances in our understanding of the biology and pathology of lymphoproliferative disorders, permitted mainly by new diagnostic tools, constantly change our approach to this heterogenous group of disorders. In this review of the more indolent subgroup of lymphoproliferative disorders, some of the recent advances...

    journal_title:Oncology

    pub_type: 杂志文章,评审

    doi:10.1159/000227602

    authors: Eek R,Falkson G

    更新日期:1997-11-01 00:00:00

  • In vitro-in vivo correlation in anticancer drug sensitivity test using AUC-based concentrations and collagen gel droplet-embedded culture.

    abstract::To improve the ability of an in vitro drug sensitivity test to predict in vivo effects, we applied a drug concentration that was pharmacokinetically equivalent to plasma levels and collagen gel droplet-embedded culture with a high cloning efficiency. We reported that the cell-killing effect of cell cycle phase-nonspec...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000227569

    authors: Inaba M,Tashiro T,Sato S,Ohnishi Y,Tanisaka K,Kobayashi H,Koezuka M

    更新日期:1996-05-01 00:00:00